Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2022

View Archived Issues

Almac Discovery selects peptide-drug conjugate ADP-c389 for preclinical development

Expanded collaboration research on COVID-19 protease inhibitors

Researchers present novel Hermansky-Pudlak syndrome murine model

New MAP4K 1inhibitors identified at Merck & Co.

Kronos Bio synthesizes new PROTAC CDK9 degradation inducers

Mirati Therapeutics, Array BioPharma present KRAS Gly12Asp inhibitors

New Ret inhibitors discovered at Lilly

Scorpion Therapeutics patents EGFR and/or HER2 inhibitors

ATAD3A is a therapeutic target in Alzheimer's disease

Novel NPR-C activator for the treatment of cardiovascular disease

SMARD1 murine model shows respiratory defects and muscular atrophy

Discovery of EGFR inhibitors against L858R/T790M/C797S resistance mutations

New STING modulators display potent immune activation and in vivo activity

Kavli Neuroscience Prize honors four for genetic discoveries

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...